Session date: 
05/12/2020 - 12:00pm to 1:00pm
Primary Biliary Cholangitis
•Describe the impact of non-alcoholic fatty liver disease (NAFLD) from an epidemiologic perspective

•Recognize specific recommendations regarding lifestyle modifications for patients with NAFLD

•Identify currently recommended pharmacologic treatments for NASH and those undergoing development

 

ATTENDANCE / CREDIT
Upon completion of each End Stage Liver Disease TeleECHO session, a short survey will be sent to each participant.  Every 3 months, a longer survey will be used. The receipt of the completed survey is required prior to receiving your CME credit. Please send completed surveys to ARZPROJECTECHO@mayo.edu.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

Presenter: 
Dr. David Chascsa
Co-presenter: 
Dr. Rolland Dickson
Where did the idea for the course originate?: 
Arizona
Please login or register to take this course.
Where did the idea for the course originate?: 
Arizona